Company intelligence / Profile preview
Curacyte AG
Munich, Bavaria, Germanycuracyte.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Curacyte AG was a Munich-based biopharmaceutical company focused on developing novel therapeutics for acute and critical care settings. Its main asset was hemoximer (Pyridoxalated Hemoglobin Polyoxyethylene, PHP), which entered pivotal Phase III trials for catecholamine-resistant distributive shock. In August 2008, it sold its subsidiary Curacyte Discovery GmbH—developer of synthetic serine protease inhibitors such as CU‑2010—to The Medicines Company. There have been no significant public updates since this transaction.
- Therapeutic areas
- CardiovascularHematology
- Modalities
- Synthetic serine protease inhibitors (via former subsidiary)Modified hemoglobin-based therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sale/acquisition partnership with The Medicines Company regarding the synthetic serine protease inhibitor program.
Beyond the preview
Go deeper on Curacyte AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curacyte AG.